| 词条 | Bazedoxifene/conjugated estrogens |
| 释义 |
| type = combo | component1 = Bazedoxifene | class1 = Selective estrogen receptor modulator | component2 = Conjugated estrogens | class2 = Estrogen | tradename = Duavee | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = By mouth | ChemSpiderID = None | ATC_prefix = G03 | ATC_suffix = CC07 }} The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis. It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer. Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet. Pfizer expects the drug to become available in the first quarter of 2014.[1] See also
References1. ^https://www.wsj.com/article/PR-CO-20131003-910561.html {{Estrogens and antiestrogens}}{{Estrogen receptor modulators}}{{DEFAULTSORT:Bazedoxifene conjugated estrogens}}{{Genito-urinary-drug-stub}} 3 : Combination drugs|Pfizer|Pfizer products |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。